{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Breast+Cancer%2C+Metastatic&page=7", "query": { "condition": "Breast Cancer, Metastatic", "page": 7 }, "page_size": 10 }, "pagination": { "page": 7, "page_size": 10, "total_count": 2407, "total_pages": 241, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Breast+Cancer%2C+Metastatic&page=8&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Breast+Cancer%2C+Metastatic&page=6&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-12T23:06:45.748Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00580112", "title": "An Efficacy Study of Trabectedin in the Treatment of Participants With Specific Subtypes of Metastatic Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Neoplasms" ], "interventions": [ { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Trabectedin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Johnson & Johnson Pharmaceutical Research & Development, L.L.C.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 127, "start_date": "2007-06", "completion_date": "2011-08", "has_results": false, "last_update_posted_date": "2014-02-25", "last_synced_at": "2026-10-12T23:06:45.748Z", "location_count": 21, "location_summary": "Sedona, Arizona • Denver, Colorado • Torrington, Connecticut + 18 more", "locations": [ { "city": "Sedona", "state": "Arizona" }, { "city": "Denver", "state": "Colorado" }, { "city": "Torrington", "state": "Connecticut" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Westminster", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00580112" }, { "nct_id": "NCT00043394", "title": "CPG 7909 Plus Herceptin® In Patients With Metastatic Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Carcinoma, Breast" ], "interventions": [ { "name": "0.04 mg/kg CpG 7909", "type": "DRUG" }, { "name": "Herceptin®", "type": "DRUG" }, { "name": "0.08 mg/kg CpG 7909", "type": "DRUG" }, { "name": "0.12 mg/kg CpG 7909", "type": "DRUG" }, { "name": "0.16 mg/kg CpG 7909", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 16, "start_date": "2002-09", "completion_date": "2003-10", "has_results": false, "last_update_posted_date": "2009-03-12", "last_synced_at": "2026-10-12T23:06:45.748Z", "location_count": 12, "location_summary": "Berkely, California • Orange, California • Palm Springs, California + 9 more", "locations": [ { "city": "Berkely", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Palm Springs", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00043394" }, { "nct_id": "NCT00777101", "title": "Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Breast Cancer", "Breast Cancer" ], "interventions": [ { "name": "Neratinib", "type": "DRUG" }, { "name": "Lapatinib", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Puma Biotechnology, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 233, "start_date": "2009-02-04", "completion_date": "2018-06-03", "has_results": true, "last_update_posted_date": "2018-08-09", "last_synced_at": "2026-10-12T23:06:45.748Z", "location_count": 44, "location_summary": "Tucson, Arizona • Murrieta, California • Orange, California + 40 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Murrieta", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Palm Springs", "state": "California" }, { "city": "Santa Rosa", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00777101" }, { "nct_id": "NCT01575522", "title": "Tivantinib in Treating Patients With Recurrent or Metastatic Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Estrogen Receptor Negative", "HER2/Neu Negative", "Progesterone Receptor Negative", "Recurrent Breast Carcinoma", "Stage IV Breast Cancer", "Triple-Negative Breast Carcinoma" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Tivantinib", "type": "DRUG" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 22, "start_date": "2012-03", "completion_date": "2013-07", "has_results": true, "last_update_posted_date": "2016-03-21", "last_synced_at": "2026-10-12T23:06:45.748Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01575522" }, { "nct_id": "NCT00001832", "title": "Lymphocyte Re-infusion During Immune Suppression to Treat Metastatic Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma", "Neoplasm Metastasis" ], "interventions": [ { "name": "gp100:209-217 (210M)", "type": "DRUG" }, { "name": "Montanide ISA-51", "type": "DRUG" }, { "name": "IL-2", "type": "DRUG" }, { "name": "MART-1:26-35(27L)", "type": "DRUG" }, { "name": "Abl cells", "type": "BIOLOGICAL" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "GCSF (Growth colony stimulating factor)", "type": "BIOLOGICAL" }, { "name": "Apheresis", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "PROCEDURE" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "7 Years", "maximum_age": null, "sex": "ALL", "summary": "7 Years and older" }, "enrollment_count": 170, "start_date": "1999-08", "completion_date": "2010-05", "has_results": true, "last_update_posted_date": "2012-12-21", "last_synced_at": "2026-10-12T23:06:45.748Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00001832" }, { "nct_id": "NCT04450706", "title": "Functional Precision Oncology for Metastatic Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "HER2-negative Breast Cancer" ], "interventions": [ { "name": "Precision Medicine", "type": "OTHER" }, { "name": "Physican Decision Making", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "University of Utah", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2021-02-16", "completion_date": "2024-09-05", "has_results": false, "last_update_posted_date": "2024-10-28", "last_synced_at": "2026-10-12T23:06:45.748Z", "location_count": 1, "location_summary": "Salt Lake City, Utah", "locations": [ { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT04450706" }, { "nct_id": "NCT00003899", "title": "Chemotherapy Plus Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "melphalan", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" }, { "name": "thiotepa", "type": "DRUG" }, { "name": "autologous bone marrow transplantation", "type": "PROCEDURE" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": null, "start_date": "1999-01", "completion_date": "2001-11", "has_results": false, "last_update_posted_date": "2016-10-04", "last_synced_at": "2026-10-12T23:06:45.748Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003899" }, { "nct_id": "NCT01042925", "title": "Study of XL147 (SAR245408) in Combination With Trastuzumab or Paclitaxel and Trastuzumab in Subjects With Metastatic Breast Cancer Who Have Progressed on a Previous Trastuzumab-based Regimen", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Breast Cancer", "Breast Neoplasms" ], "interventions": [ { "name": "XL147 (SAR245408)", "type": "DRUG" }, { "name": "trastuzumab", "type": "BIOLOGICAL" }, { "name": "paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 42, "start_date": "2010-02", "completion_date": "2012-12", "has_results": false, "last_update_posted_date": "2016-06-03", "last_synced_at": "2026-10-12T23:06:45.748Z", "location_count": 8, "location_summary": "Los Angeles, California • Fort Meyers, Florida • Boston, Massachusetts + 4 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Fort Meyers", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Detroit", "state": "Michigan" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01042925" }, { "nct_id": "NCT00041808", "title": "Magnetic-Targeted Doxorubicin in Treating Patients With Cancer Metastatic to the Liver", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastases, Neoplasm", "Colorectal Neoplasms", "Esophageal Neoplasms", "Stomach Neoplasms", "Pancreatic Neoplasms", "Breast Neoplasms", "Melanoma", "Sarcoma", "Gastrointestinal Neoplasms", "Lung Neoplasms", "Liver Neoplasms", "Cholangiocarcinoma" ], "interventions": [ { "name": "MTC-DOX for Injection", "type": "DRUG" }, { "name": "Chemotherapy", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "FeRx", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 20, "start_date": "2001-07", "completion_date": "2003-04", "has_results": false, "last_update_posted_date": "2005-06-24", "last_synced_at": "2026-10-12T23:06:45.748Z", "location_count": 3, "location_summary": "San Diego, California • San Francisco, California • Temple, Texas", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Temple", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00041808" }, { "nct_id": "NCT00003440", "title": "Paclitaxel With or Without Trastuzumab in Treating Patients With or Without HER-2/Neu Breast Cancer That is Inoperable, Recurrent, or Metastatic", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HER2-negative Breast Cancer", "HER2-positive Breast Cancer", "Recurrent Breast Cancer", "Stage IIIC Breast Cancer", "Stage IV Breast Cancer" ], "interventions": [ { "name": "paclitaxel", "type": "DRUG" }, { "name": "trastuzumab", "type": "BIOLOGICAL" }, { "name": "quality-of-life assessment", "type": "PROCEDURE" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "PROCEDURE", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 580, "start_date": "1998-07", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-06-04", "last_synced_at": "2026-10-12T23:06:45.748Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003440" } ] }